Rosiglitazone

Results: 280



#Item
71U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
72Microsoft PowerPoint - GSK presentation July 13 Adcom.pptx

Microsoft PowerPoint - GSK presentation July 13 Adcom.pptx

Add to Reading List

Source URL: www.fda.gov

Language: English
73U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
74Cardiovascular Events in the RECORD Trial Thomas A. Marciniak, M.D. Division of Cardiovascular and Renal Products

Cardiovascular Events in the RECORD Trial Thomas A. Marciniak, M.D. Division of Cardiovascular and Renal Products

Add to Reading List

Source URL: www.fda.gov

Language: English
75Trust and Integrity in Medicine: Rosiglitazone

Trust and Integrity in Medicine: Rosiglitazone

Add to Reading List

Source URL: www.fda.gov

Language: English
76Advisory Committee Meeting Avandia® (rosiglitazone maleate) July 13-14, 2010 Mary H. Parks, M.D. Division of Metabolism and Endocrinology Products

Advisory Committee Meeting Avandia® (rosiglitazone maleate) July 13-14, 2010 Mary H. Parks, M.D. Division of Metabolism and Endocrinology Products

Add to Reading List

Source URL: www.fda.gov

Language: English
77U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
78Lesion Progression and Restenosis in PTCA-Treated Patients with Multivessel Disease

Lesion Progression and Restenosis in PTCA-Treated Patients with Multivessel Disease

Add to Reading List

Source URL: www.fda.gov

Language: English
79FDA Cardiologist’s Perspective on RECORD Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Avandia® (rosiglitazone) – July 13-14, 2

FDA Cardiologist’s Perspective on RECORD Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Avandia® (rosiglitazone) – July 13-14, 2

Add to Reading List

Source URL: www.fda.gov

Language: English
80Spring 2011 Newsletter.pub

Spring 2011 Newsletter.pub

Add to Reading List

Source URL: www.kdheks.gov

Language: English - Date: 2012-02-06 11:14:56